Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

BRAF and MEK inhibitors have improved outcomes for patients with BRAF-mutant melanoma, but their efficacy is limited by both intrinsic and acquired resistances. Activation of the PI3K pathway can mediate resistance to these agents, providing a strong rationale for combination therapy in melanoma. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Sweetlove, Melanie, Wrightson, Emma, Kolekar, Sharada, Rewcastle, Gordon W., Baguley, Bruce C., Shepherd, Peter R., Jamieson, Stephen M. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468830/
https://www.ncbi.nlm.nih.gov/pubmed/26137449
http://dx.doi.org/10.3389/fonc.2015.00135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468830/
https://www.ncbi.nlm.nih.gov/pubmed/26137449
http://dx.doi.org/10.3389/fonc.2015.00135

Ejemplares similares